On 14 November 2026 China published two lists on the same day: the ninth adjustment of the National Reimbursement Drug List since the National Healthcare Security Administration was created, and the country's first commercial health insurance catalog for innovative drugs. The adjustment adds 107 medicines, 51 of them Class 1 innovative drugs — a record for a single round — spanning oncology, rare disease, chronic disease and mental health, according to the report carried by Eastmoney / Time Finance. Among the entries is a "million-tier" CAR-T cell therapy from JW Therapeutics (药明巨诺), relmacabtagene autoleucel (瑞基奥仑赛, marketed as 倍诺达), listed for the first time.
You almost certainly cannot claim from any of this. International patients are not enrolled in China's basic medical insurance, and a visiting patient with a foreign passport has no line item in the reimbursement system. The catalog still matters, because it sets the pricing floor and the supply stability of exactly the drugs you are flying in for — and because this year, for the first time, there is a commercial-insurance payment lane attached to it.
What the 2026 Adjustment Actually Changed
Three developments in this round are directly relevant to a foreign patient comparing destinations for advanced cancer therapy.
A high-cost cell therapy entered the list. The inclusion of a CAR-T product that Chinese media themselves describe as "million-tier" signals that China is willing to negotiate cell therapies into routine procurement rather than leaving them as a luxury paid entirely from the patient's pocket. Where those medicines are stocked and priced after negotiation, the self-pay price at the same hospital is no longer set by import scarcity.
An innovative drug was listed in its approval year. Baili's lulunatuomab-type EGFR×HER3 bispecific antibody-drug conjugate (百利天恒, 伦康依隆妥单抗, brand 宜泽康) — described in the coverage as the world's first EGFR×HER3 bispecific ADC — made it into the catalog through the newly implemented pre-submission (预申报) mechanism, which lets a file enter review ahead of the ordinary annual window. For you, the practical consequence is shorter "approval-to-shelf" lag: the molecule is not a trial-only drug in China.
A chronic-disease blockbuster lowered the whole bill. Innovent's mazdutide (信达生物, 玛仕度肽注射液, 信尔美), China's first original dual-target weight-and-glucose agent for adult type 2 diabetes, is also listed. It matters here mainly as evidence of direction: China's catalog is now absorbing first-in-class domestic molecules quickly, and the price anchors for those classes move down with them.
The parallel commercial catalog is the structural change. It does not pay for you, but it creates a domestic insurance lane for exactly the products that were previously pure self-pay.
Why a Catalog You Cannot Use Sets Your Invoice
Three mechanisms transfer a reimbursement decision onto a foreign patient's bill.
First, price anchoring. Chinese public hospitals are required to sell listed drugs inside a negotiated price frame, and departments build treatment pathways around what the hospital can actually procure at that price. Self-pay tariffs at public hospitals are normally derived from that same price base plus a service margin, not from a separate "foreigner rate" for the drug itself.
Second, availability. A medicine in the catalog is on the hospital's formulary, replenished through a procurement channel, and present in the pharmacy. A medicine outside it is either bought ad hoc or only exists inside a clinical trial — which changes your timeline from weeks to "when a slot opens."
Third, competitive pressure on locally made cell and ADC therapies. When domestic CAR-T and bispecific ADC products reach scale inside a national purchasing scheme, the Western list prices for the same class — commonly reported in the hundreds of thousands of US dollars per course — are the comparison, not the ceiling, for what a Chinese centre quotes. The honest statement is directional rather than numeric: the Chinese self-pay figure for these classes has repeatedly been reported as a fraction of US list pricing, and the specific number must come from a written quotation from the treating centre. Any article that gives you a fixed CAR-T price without a dated quote behind it is guessing. If you want the wider cost picture, our breakdown of CAR-T therapy cost in China explains which line items move the total.
The Three Therapy Classes Most Affected by the 2026 Round
| Therapy / product | What the 2026 round did | What determines your actual cost | Status for a foreign patient |
|---|---|---|---|
| CAR-T cell therapy (relmacabtagene autoleucel, JW Therapeutics) | First inclusion of a "million-tier" CAR-T in the national catalog | Apheresis and manufacturing, conditioning chemotherapy, hospital days, ICU and supportive care, and any bridging therapy before infusion | Self-pay, or reimbursement by your own international policy; typically used in relapsed/refractory B-cell malignancies, with eligibility set by the centre |
| Bispecific ADC (EGFR×HER3, Baili 宜泽康) | Listed in the same year as approval via the pre-submission mechanism | Cycles required, weight-based dosing, on-target toxicity management, pre-medication | Available in listed hospitals on a prescription basis; access is a physician decision |
| Dual-target GLP-1/GCG agonist (mazdutide, Innovent 信尔美) | Listed for adult type 2 diabetes | Treatment duration, dose escalation schedule, and whether your home physician will co-manage follow-up | Commonly prescribed for metabolic indications; long-term follow-up planning matters for travellers |
A separate but related signal came on 4 November, when Sino Biopharm and Boehringer Ingelheim announced a multi-project option and license agreement covering antibody-drug conjugates and T-cell engagers: six preclinical programmes, five from 礼新医药 and one from Beijing 泰德, with US$358 million in upfront and near-term payments and up to US$7 billion in potential downstream payments and royalties. Deals like this push Chinese-origin molecules into international multi-centre development, which is how a patient who has already progressed on standard therapy can sometimes access a drug through a trial arm rather than a price list. See our guide to cancer treatment in China for how the trial and named-patient routes differ in practice.
Which Payment Path Is Real for You
| Path | Who it genuinely fits | What you must show | Main limitation |
|---|---|---|---|
| Direct self-pay | The large majority of international patients | Passport, medical records, pathology and imaging, proof of funds | Full exposure to the quoted price; ask for a written, itemised quotation before booking |
| Your own international health / evacuation policy | Expats and residents abroad with comprehensive cover | Pre-authorisation letter, treatment plan in English, coded estimate from the Chinese hospital | Many policies exclude cell therapy or cap it; oncology clauses need reading, not assuming |
| Chinese commercial innovative-drug products | Foreigners employed in China who already hold a qualifying local policy | Chinese policy number and insurer eligibility confirmation | Published catalog ≠ your policy pays; insurer terms govern |
| Clinical trial enrolment | Patients who progressed on standard lines and meet protocol criteria | Translated records, staging data, prior-line history, organ-function labs | Slot availability, travel and residency logistics, protocol-defined visits |
| Basic medical insurance | Not available to visiting international patients | — | Excluded by design |
Two points deserve emphasis. The new commercial catalog is a genuine addition — but it is a lane for people inside the Chinese commercial insurance system, not for a patient flying in for one admission. And no payment path substitutes for clinical eligibility: whether CAR-T, a bispecific ADC or a trial is appropriate for you must be assessed in person by a licensed physician, based on your histology, molecular profile, performance status and prior treatment. A blog post, including this one, cannot reach that decision.
A Realistic Planning Sequence
Start with records, not with travel. A complete packet — discharge summaries, pathology slides and blocks or scans, next-generation sequencing if you have it, the last three cycles of treatment dates — is what makes a remote opinion meaningful rather than generic. Send it for a case evaluation and ask specifically whether the newly listed products are stocked at the centres that would treat you, and whether any trial is open.
Then ask for a written, dated quotation with line items: drug, apheresis and manufacturing (for cell therapy), admission days, intensive care contingency, pre- and post-treatment medications, and the translation and coordination fee. That document, not a headline number, is what your home insurer will pre-authorise against.
Then handle logistics in parallel. CAR-T has a manufacturing interval measured in weeks, so the apheresis date drives the trip; our CAR-T treatment service page covers how that scheduling usually works. Visa categories and their permitted stay length are dealt with in the China medical visa guide, and hospital booking in Shanghai is described under hospital appointment services.
What We Can Take Off Your Plate
OriEast works with international patients who are comparing China against other destinations on price, product availability and time-to-treatment. We translate and structure your records for a clinical review, obtain written itemised quotations from the hospitals that would treat you, coordinate appointments and interpreter support on site, and stay with you through discharge and follow-up planning.
Two steps start it: submit your condition for a case evaluation to find out whether a Chinese centre would realistically accept you, and send us an inquiry if you want a quotation, an itinerary or a hospital-booking timeline in writing before you commit to travel.